Cargando…
ARID1A alterations and their clinical significance in cholangiocarcinoma
BACKGROUND: ARID1A is a member of the SWI/SNF chromatin remodeling complex. It functions as a tumor suppressor and several therapeutic targets in ARID1A-mutated cancers are currently under development, including EZH2. A synthetic lethal relationship between ARID1A and EZH2 has been revealed in sever...
Autores principales: | Namjan, Achira, Techasen, Anchalee, Loilome, Watcharin, Sa-ngaimwibool, Prakasit, Jusakul, Apinya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719290/ https://www.ncbi.nlm.nih.gov/pubmed/33344089 http://dx.doi.org/10.7717/peerj.10464 |
Ejemplares similares
-
Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma
por: Tessiri, Supharada, et al.
Publicado: (2022) -
Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma
por: Wintachai, Preawwalee, et al.
Publicado: (2021) -
Progranulin modulates cholangiocarcinoma cell proliferation, apoptosis, and motility via the PI3K/pAkt pathway
por: Daya, Minerva, et al.
Publicado: (2018) -
In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues
por: Suksawat, Manida, et al.
Publicado: (2019) -
Zileuton suppresses cholangiocarcinoma cell proliferation and migration through inhibition of the Akt signaling pathway
por: Khophai, Sasikamon, et al.
Publicado: (2018)